We discovered that Y472CBRAF is a kinase-inactivating BRAF mutation (KIBRAF) and that NSCLC cells that harbor KIBRAF undergo senescence when exposed to dasatinib, whereas NSCLC with wild-type BRAF (WTBRAF) or kinase-activating mutations is resistant to dasatinib in vitro and in patients [3]. Here, BRAF is linked to non-small cell lung carcinoma.